Candid Therapeutics Debuts with $370M Capital Raise
SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, announced its official launch today. “TCE antibodies have the most promise as scalable and patient friendly drugs to deplete B cells for treatment of a myriad of autoimmune conditions and represents a once in a generation […]
